Zydus launches India first indigenously developed Aflibercept biosimilar Anyra

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹912.50

prior close

₹913.80

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.5%+0.3% vs market

Pharmaceuticals peers, median of 157sector-1.2%-0.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty 100 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.4

15m

+0.3

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-1.5+0.3-1.2-0.1

Next day

-1.2-1.0-0.1-1.4+0.3

-0.8-0.5-0.3-1.6+0.9

-0.6-1.4+0.8-2.1+1.5

+0.7-1.1+1.8-2.4+3.1

+2.8-1.0+3.8-2.0+4.8

-0.8-3.5+2.7-4.6+3.8

15d

-0.9-10.0+9.0-6.8+5.9

-3.7-10.7+7.0-7.5+3.8

+2.5-4.7+7.1+0.5+1.9

+11.5-7.4+18.9+3.2+8.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus launched Anyra, India's first indigenously developed Aflibercept 2 mg biosimilar, for treating eye conditions including wet Age-related Macular Degeneration, diabetic retinopathy, and macular edema. Zydus signed licensing agreements with Regeneron and Bayer. The drug targets over 10 million patients in India affected by these retinal conditions. Zydus claims India's largest biosimilar portfolio with over 13 products developed domestically.

Likely market impact

Positive for Zydus as it expands biosimilar portfolio, strengthens ophthalmic franchise, and taps large underserved patient pool in India.